Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study.

about

Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study.

Item

http://www.wikidata.org/entity/Q47594612

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Liraglutide Improves Cardiovas ...... 48-Month Retrospective Study.

@en

Liraglutide Improves Cardiovas ...... 48-Month Retrospective Study.

@nl

type

Item

label

Liraglutide Improves Cardiovas ...... 48-Month Retrospective Study.

@en

Liraglutide Improves Cardiovas ...... 48-Month Retrospective Study.

@nl

prefLabel

Liraglutide Improves Cardiovas ...... 48-Month Retrospective Study.

@en

Liraglutide Improves Cardiovas ...... 48-Month Retrospective Study.

@nl

P1476

Liraglutide Improves Cardiovas ...... 48-Month Retrospective Study.

@en

P2093

Alessandro Ciresi

http://www.w3.org/2001/XMLSchema#string

Enrica Vigneri

http://www.w3.org/2001/XMLSchema#string

Felicia Pantò

http://www.w3.org/2001/XMLSchema#string

Stefano Radellini

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

General cardiovascular risk profile for use in primary care: the Framingham Heart Study

Liraglutide is effective in type 2 diabetic patients with sustained endogenous insulin-secreting capacity.

Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk.

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.

Visceral adiposity index (VAI) is predictive of an altered adipokine profile in patients with type 2 diabetes.

Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes.

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease.

Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: A randomized, placebo-controlled, crossover study.

P2888

s13300-017-0338-4

P304

363-371

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1007/S13300-017-0338-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Carla Giordano

P577

2017-11-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29139081

http://www.w3.org/2001/XMLSchema#string

P921

metformin

P932

5801224

http://www.w3.org/2001/XMLSchema#string